Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Tremblay E. Portrait de l'usage des bisphosphonates et du denosumab chez les personnes de 50 ans ou plus souffrant d'osteoporose couvertes par le regime public d'assurance medicaments. [Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription drug insurance program] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). 2014 Authors' objectives The objectives of this study were to describe new users of alendronate, risedronate, denosumab or zoledronic acid and to assess the persistence rate and the level of compliance with these pharmacological therapies as well as with concomitantly administered calcium and vitamin D supplements. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Canada; Cost-Benefit Analysis; Diphosphonates; Humans; Imidazoles; Medication Adherence; Medication Therapy Management; Middle Aged; Osteoporosis; Treatment Outcome Country of organisation Canada English summary An English language summary is available. Address for correspondence Institut national d'excellence en santé et en services sociaux (INESSS), 1195 avenue Lavigerie, bureau 60 Québec (Québec) Canada, G1V 4N3
Email: inesss@inesss.qc.ca AccessionNumber 32015000083 Date abstract record published 09/02/2015 |